← FDA DRUG APPROVALS

FDA ANDA · ANDA090941

BUPROPION HYDROCHLORIDE

Sponsor: RISING

APPLICATION
ANDA090941
TYPE
ANDA
ORIGINAL APPROVAL
2010-05-03
LATEST ACTION
2025-11-05
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

BUPROPION HYDROCHLORIDEDiscontinued
BUPROPION HYDROCHLORIDE 150MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-11-05Labeling · Supplement 17 · standardAP
2024-05-07Labeling · Supplement 16 · standardAP
2024-04-16Labeling · Supplement 15 · standardAP
2024-04-16Labeling · Supplement 13 · standardAP
2017-04-28Labeling · Supplement 10 · standardAP
2017-04-28Labeling · Supplement 9 · standardAP
2014-11-20Labeling · Supplement 6 · standardAP
2014-11-20Labeling · Supplement 7 · standardAP
2010-05-03OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →